Evidence map›Paper›PMID 39766063›Full record

ArticleCancers2024

DHODH Inhibition Suppresses

Ioanna Tsea, Thale Kristin Olsen, Panagiotis Alkinoos Polychronopoulos, Conny Tümmler, David B Sykes, Ninib Baryawno, Cecilia Dyberg

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Cancers, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers.

0numbers the graph read from it
0cells of the map it votes in
4citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

4 citing papers in PubMed.

  1. Article
  2. Article
  3. Medulloblastoma: biology and immunotherapy.Frontiers in immunology · 2025
    Review
  4. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors.

Ioanna TseaDivision of Pediatric Oncology and Pediatric Surgery, Department of Women's and Children's Health, Karolinska Institutet, 171 77 Stockholm, Sweden.ORCID 0000-0002-6879-5490
Thale Kristin OlsenDivision of Pediatric Oncology and Pediatric Surgery, Department of Women's and Children's Health, Karolinska Institutet, 171 77 Stockholm, Sweden.
Panagiotis Alkinoos PolychronopoulosDivision of Pediatric Oncology and Pediatric Surgery, Department of Women's and Children's Health, Karolinska Institutet, 171 77 Stockholm, Sweden.ORCID 0009-0004-3144-5712
Conny TümmlerDivision of Pediatric Oncology and Pediatric Surgery, Department of Women's and Children's Health, Karolinska Institutet, 171 77 Stockholm, Sweden.ORCID 0000-0002-5530-4752
David B SykesCenter for Regenerative Medicine, Massachusetts General Hospital, Boston, MA 02114, USA.
Ninib BaryawnoDivision of Pediatric Oncology and Pediatric Surgery, Department of Women's and Children's Health, Karolinska Institutet, 171 77 Stockholm, Sweden.
Cecilia DybergDivision of Pediatric Oncology and Pediatric Surgery, Department of Women's and Children's Health, Karolinska Institutet, 171 77 Stockholm, Sweden.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

BACKGROUND/

objectivesMedulloblastoma (MB) is the most common high-grade paediatric brain tumour, with group 3 MB patients having the worst prognosis. A high prevalence of group 3 tumours shows overexpression of the

methodsIn this study, we investigated the efficacy of brequinar, a DHODH inhibitor, in MB, with a focus on group 3. In vitro, BRQ's effects on cell viability and MYC expression were tested in seven MB cell lines. In vivo, a novel zebrafish xenograft model was used to evaluate BRQ's impact on tumour growth and toxicity.

resultsHigh

conclusionsOur findings indicate that DHODH is a promising therapeutic target in group 3 MBs. Furthermore, BRQ shows potential for clinical application, effectively reducing tumour growth and

Indexed as

brequinarDHODHmedulloblastomapaediatric cancersrelapsetargeted therapy

Identifiers

PMID39766063
PMCPMC11674817

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.